Invasive candidiasis: Investigational drugs in the clinical development pipeline and mechanisms of action
出版年份 2022 全文链接
标题
Invasive candidiasis: Investigational drugs in the clinical development pipeline and mechanisms of action
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages -
出版商
Informa UK Limited
发表日期
2022-06-03
DOI
10.1080/13543784.2022.2086120
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Let's talk about sex characteristics—As a risk factor for invasive fungal diseases
- (2022) Matthias Egger et al. MYCOSES
- Therapeutic potential of Fosmanogepix (APX001) for intra-abdominal candidiasis: from lesion penetration to efficacy in a mouse model
- (2021) Annie Lee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colonisation and Transmission Dynamics of Candida auris among Chronic Respiratory Diseases Patients Hospitalised in a Chest Hospital, Delhi, India: A Comparative Analysis of Whole Genome Sequencing and Microsatellite Typing
- (2021) Anamika Yadav et al. Journal of Fungi
- Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata
- (2021) Ahmed Gamal et al. Frontiers in Cellular and Infection Microbiology
- Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
- (2021) Sabelle Jallow et al. Journal of Fungi
- Preliminary Characterisation of NP339, a Novel Polyarginine Peptide with Broad Antifungal Activity
- (2021) Vanessa Duncan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Transient Mitochondria Dysfunction Confers Fungal Cross-Resistance against Phagocytic Killing and Fluconazole
- (2021) Sofía Siscar-Lewin et al. mBio
- Antifungal Pipeline
- (2021) Todd Patrick McCarty et al. Frontiers in Cellular and Infection Microbiology
- Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018–2019)
- (2021) Michael A. Pfaller et al. Journal of Global Antimicrobial Resistance
- LncRNA DINOR is a virulence factor and global regulator of stress responses in Candida auris
- (2021) Jiaxin Gao et al. Nature Microbiology
- Update 2016–2018 of the Nationwide Danish Fungaemia Surveillance Study: Epidemiologic Changes in a 15-Year Perspective
- (2021) Malene Risum et al. Journal of Fungi
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
- (2021) Martin Hoenigl et al. DRUGS
- Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis
- (2021) Jack D Sobel et al. Future Microbiology
- An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis
- (2021) Semra Palić et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- The long non-coding RNA landscape of Candida yeast pathogens
- (2021) Hrant Hovhannisyan et al. Nature Communications
- Rezafungin In Vitro Activity against Contemporary Clinical Nordic Candida Isolates and Candida auris Determined by the EUCAST Reference Method
- (2020) Marie Helleberg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pan-resistant Candida auris Isolates from the Outbreak in New York are Susceptible to Ibrexafungerp: A Glucan Synthase Inhibitor
- (2020) Yan Chun Zhu et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Drug resistance and tolerance in fungi
- (2020) Judith Berman et al. NATURE REVIEWS MICROBIOLOGY
- Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae
- (2020) Abhilash Kannan et al. mBio
- Nanocarriers Provide Sustained Antifungal Activity for Amphotericin B and Miltefosine in the Topical Treatment of Murine Vaginal Candidiasis
- (2020) Fernanda Walt Mendes da Silva de Bastiani et al. Frontiers in Microbiology
- Hope on the Horizon: Novel Fungal Treatments in Development
- (2020) Adriana M Rauseo et al. Open Forum Infectious Diseases
- Manogepix (APX001A) displays potent in vitro activity against human pathogenic yeast, but with an unexpected correlation to fluconazole MICs
- (2020) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Enhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility
- (2020) Sean D. Liston et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail
- (2020) B. Elewski et al. BRITISH JOURNAL OF DERMATOLOGY
- Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure
- (2020) Amir Arastehfar et al. MYCOSES
- Antimicrobial peptides: Application informed by evolution
- (2020) Brian P. Lazzaro et al. SCIENCE
- Antifungal Activity and Mode of Action of Miltefosine Against Clinical Isolates of Candida krusei
- (2020) Yongqin Wu et al. Frontiers in Microbiology
- Unmasking the Amphotericin B Resistance Mechanisms in Candida haemulonii Species Complex
- (2020) Laura N. Silva et al. ACS Infectious Diseases
- Manogepix (APX001A) in vitro activity against Candida auris. A head to head comparison of EUCAST and CLSI MICs.
- (2020) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris
- (2020) Thayná Lopes Barreto et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs
- (2020) Robert T Todd et al. eLife
- Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?
- (2020) Maria Aigner et al. Journal of Fungi
- In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak
- (2020) YanChun Zhu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis
- (2020) Stephen R Brand et al. CLINICAL INFECTIOUS DISEASES
- Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis- The STRIVE Trial
- (2020) George R Thompson et al. CLINICAL INFECTIOUS DISEASES
- The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
- (2020) Amir Arastehfar et al. Journal of Fungi
- Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections
- (2020) Karen Joy Shaw et al. Journal of Fungi
- Oral ibrexafungerp efficacy and safety in the treatment of vulvovaginal candidiasis: A phase 3, randomized, blinded, study vs. placebo (VANISH-303)
- (2020) J.R. Schwebke et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen Candida auris
- (2020) Kali R. Iyer et al. Nature Communications
- Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016
- (2019) Michael A Pfaller et al. Open Forum Infectious Diseases
- In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans
- (2019) Andrew T. Nishimoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects
- (2019) Laura L. Kovanda et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Novel Arylamidine T-2307 Selectively Disrupts Yeast Mitochondrial Function by Inhibiting Respiratory Chain Complexes
- (2019) Kohei Yamashita et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis
- (2019) Cristina de Castro Spadari et al. International Journal of Nanomedicine
- MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis
- (2019) Andrej Spec et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ibrexafungerp: A novel oral glucan synthase inhibitor
- (2019) M R Davis et al. MEDICAL MYCOLOGY
- Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology
- (2019) Oliver A. Cornely et al. MYCOSES
- Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
- (2019) Nathan P. Wiederhold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A First-in-Human Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of a Novel Antifungal Drug VL-2397 in Healthy Adults
- (2019) Mammen P. Mammen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161
- (2019) Andrew T. Nishimoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ASP2397 Is a Novel Natural Compound That Exhibits Rapid and Potent Fungicidal Activity against Aspergillus Species through a Specific Transporter
- (2019) Ikuko Nakamura et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397
- (2019) Anna-Maria Dietl et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations
- (2019) Natalie S. Nunnally et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of a novel 1,3-beta-D-glucan Synthase Inhibitor, Ibrexafungerp (formerly SCY-078), Against Candida glabrata
- (2019) M. Ghannoum et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae
- (2019) Zoltán Tóth et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
- (2019) Mili Kapoor et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans
- (2019) Andrew T Nishimoto et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In Vitro Antifungal Susceptibility of the Emerging Multidrug-Resistant Pathogen Candida auris to Miltefosine Alone and in Combination with Amphotericin B
- (2019) Yongqin Wu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris
- (2019) Nathan P. Wiederhold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects
- (2019) Shawn Flanagan et al. Clinical Pharmacology in Drug Development
- A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis
- (2018) Stephen R. Brand et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model
- (2018) Miao Zhao et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
- (2018) Christopher L. Hager et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis
- (2018) M. Ghannoum et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method
- (2018) M.C. Arendrup et al. CLINICAL MICROBIOLOGY AND INFECTION
- The antifungal arsenal: alternative drugs and future targets
- (2018) Nathan P. Wiederhold INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model
- (2018) Christopher L Hager et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Invasive candidiasis
- (2018) Peter G. Pappas et al. Nature Reviews Disease Primers
- SCY-078, A Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections During Mass Balance Studies with IV and PO 14C-SCY-078 in Albino and Pigmented Rats
- (2018) Stephen Wring et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- MSH2 Gene Point Mutations Are Not Antifungal Resistance Markers in Candida glabrata
- (2018) María Ángeles Bordallo-Cardona et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular mechanisms of azole resistance in Candida tropicalis isolates causing invasive candidiasis in China
- (2018) X. Fan et al. CLINICAL MICROBIOLOGY AND INFECTION
- Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species
- (2018) José F. Muñoz et al. Nature Communications
- 1413. A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intravenous Therapies
- (2018) Lilian Kibathi et al. Open Forum Infectious Diseases
- CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program
- (2017) Michael A. Pfaller et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.
- (2017) Laura Judith Marcos-Zambrano et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen
- (2017) Hiroshi Nishikawa et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
- (2017) Michael R Hodges et al. Open Forum Infectious Diseases
- Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis
- (2017) Christopher M Rubino et al. Open Forum Infectious Diseases
- Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability
- (2017) Michael R Hodges et al. Open Forum Infectious Diseases
- Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
- (2016) Voon Ong et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties
- (2016) Kenneth D. James et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
- (2016) Taylor Sandison et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Miltefosine inhibits Candida albicans and non- albicans Candida spp. biofilms and impairs the dispersion of infectious cells
- (2016) Taissa Vila et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- ASP2397: a novel antifungal agent produced by Acremonium persicinum MF-347833
- (2016) Ikuko Nakamura et al. JOURNAL OF ANTIBIOTICS
- T-2307, a novel arylamidine, is transported intoCandida albicansby a high-affinity spermine and spermidine carrier regulated by Agp2
- (2016) Hiroshi Nishikawa et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, againstCandidaandAspergillusspp., including echinocandin- and azole-resistant isolates
- (2016) Michael A. Pfaller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance
- (2016) Kelley R. Healey et al. Nature Communications
- Fluconazole and Echinocandin Resistance of Candida glabrata Correlates Better with Antifungal Drug Exposure Rather than with MSH2 Mutator Genotype in a French Cohort of Patients Harboring Low Rates of Resistance
- (2016) Sarah Dellière et al. Frontiers in Microbiology
- Mechanism Matters: A Taxonomy of Cell Penetrating Peptides
- (2015) W. Berkeley Kauffman et al. TRENDS IN BIOCHEMICAL SCIENCES
- Strategic Approaches to Optimizing Peptide ADME Properties
- (2014) Li Di AAPS Journal
- The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme
- (2014) A. G. S. Warrilow et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Contribution of Clinically Derived Mutations inERG11to Azole Resistance in Candida albicans
- (2014) Stephanie A. Flowers et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Design and optimization of highly-selective fungal CYP51 inhibitors
- (2014) William J. Hoekstra et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Rapid Emergence of Echinocandin Resistance during Candida kefyr Fungemia Treatment with Caspofungin
- (2013) A. Fekkar et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Enfumafungin Derivative MK-3118 Shows IncreasedIn VitroPotency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates
- (2013) Cristina Jiménez-Ortigosa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- T-2307 Causes Collapse of Mitochondrial Membrane Potential in Yeast
- (2012) Tatsuya Shibata et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice
- (2011) Sélène Ferrari et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis
- (2011) Katsura Hata et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis
- (2011) Nao-aki Watanabe et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method
- (2011) Michael A. Pfaller et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- T-2307 Shows Efficacy in a Murine Model of Candida glabrata Infection despite In Vitro Trailing Growth Phenomena
- (2010) E. Yamada et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Uptake of T-2307, a novel arylamidine, in Candida albicans
- (2010) H. Nishikawa et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine
- (2008) J. Mitsuyama et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility
- (2008) G. Garcia-Effron et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started